A Phase 4 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 19 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 13th largest by enrollment, is one of 5 that started in 2013, is one of 2 in phase 4, and was the 14th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 52 across the 21 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 7 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Arthritis, Juvenile by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Arthritis, Juvenile by Hoffmann-La Roche, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2013, is one of 2 in phase 4, and was the 12th registered.
Hoffmann-La Roche’s Arthritis, Juvenile studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 17 in Arthritis, Juvenile:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks. Participants who experience a laboratory abnormality during Part 1 may be eligible to move into Part 2 of the study.
PART 2 This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of tocilizumab in reduced dose frequency in participants with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice weekly tocilizumab dosing, that has since resolved. Participants will receive tocilizumab 12 mg/kg or 8 mg/kg intravenously every 3 weeks. After 5 consecutive infusions, participants who experience an event of neutropenia, thrombocytopenia or liver enzyme abnormality will move to every 4 weeks tocilizumab administration. Anticipated time on study treatment is 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PART 1 and 2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants \< 30 kg; 8 mg/kg for participants \>/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
Drug: Tocilizumab
Participants with weight \< 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
Drug: Tocilizumab
Participants with weight \>/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
Drug: Tocilizumab
Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
Also known as: RoActemra/Actemra
Juvenile Arthritis Disease Activity Score (JADAS-71)
JADAS-71 has 4 components: Physician global assessment of disease activity on a visual analog scale (VAS) (range=0-10, left end of line=arthritis inactive, i.e., symptom-free and no arthritis symptoms; right end=arthritis very active), patient/parent global assessment of overall well-being on VAS (range=0-10, left end of line=very well, right end=very poor), normalized erythrocyte sedimentation rate (ESR) (range=0-10, If ESR is ≤20 mm/h, set to 0. If ≥120 mm/h, set to 10 mm/h. If \> 20 mm/h and \< 120 mm/h, apply formula: \[ESR-20 mm/h\]/10 mm/h), and a count of active arthritis (swelling present or pain present and limitation of motion) in 71 selected joints (range=0-71). JADAS-71 is sum of 4 component scores, range=0-101. A higher score=more arthritis disease activity. Data reported for up to Week 52 was collected in Part 2: Q3W arms: Baseline, Weeks 3,6,9,12,24,36,48 and 51; Q4W arms: Baseline, Weeks 0,4,8,12,24,36 and 40.
Time frame: Part 2: Up to 52 weeks
Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study
JIA flare was defined as any 3 of the 6 core outcome variables worsening by at least 30% relative to baseline visit of Part 2, with no more than 1 of the remaining variables improving by more than 30%. For the number of joints with active arthritis or the number of joints with limitation of motion a minimum worsening of at least 2 joints had to be present. If the physician global assessment (PGA) or the parent/patient global assessment were used a minimum worsening of at least 2 units on a scale from 0 to 10 had be present. For erythrocyte sedimentation rate (ESR), a worsening of at least 30% was not considered if within normal ranges. The 6 core outcome variables: PGA of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis, number of joints with limitation of movement, ESR (measure of acute phase reaction) and functional ability determined by Childhood Health Assessment Questionnaire (CHAQ) Disability Index.
Time frame: Part 2: Up to 52 weeks
Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study
Absence of fever at screening visit was defined as a temperature measurement \< 38 degree centigrades (C). Presence of fever at each study visit was defined as a temperature measurement ≥ 38 C.
Time frame: Part 2: Up to 52 weeks
Number of Participants With at Least One Adverse Event
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Part 1 - Baseline up to 24 weeks plus 12 weeks of safety follow up; Part 2 - Baseline up to 52 weeks plus 12 weeks of safety follow up
Serum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study
Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Soluble IL-6 Receptor (sIL-6R) Protein Concentration in Part 2 of the Study
Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
C-reactive Protein (CRP) Concentration in Part 2 of the Study
Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Erythrocyte Sedimentation Rate (ESR) in Part 2 of the Study
Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study
Time frame: Part 2: Up to Week 52
Serum TCZ Concentration in Part 2 of the Study
Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study
CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability.
Time frame: Baseline of Part 2
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study
CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability. Negative change from baseline indicates an improvement.
Time frame: Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40
Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study
Participant's/parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity).
Time frame: Baseline of Part 2
Change From Baseline in Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study
Participant's/Parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity). Reported is the change from baseline in VAS score with a negative change from baseline indicating an improvement.
Time frame: Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40
Participants with systemic juvenile idiopathic arthritis (sJIA) were recruited at study sites in 8 countries. The study consisted of two parts: Part 1 was a 24-week Run-in period and Part 2 was a 52-week Main study.
| Milestone | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W |
|---|---|---|---|
| Started | 19 | 0 | 0 |
| Completed | 17 | 0 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Milestone | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W |
|---|---|---|---|
| Started | 0 | 7 | 15 |
| Completed | 0 | 5 | 8 |
| Not completed | 0 | 2 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
JADAS-71 has 4 components: Physician global assessment of disease activity on a visual analog scale (VAS) (range=0-10, left end of line=arthritis inactive, i.e., symptom-free and no arthritis symptoms; right end=arthritis very active), patient/parent global assessment of overall well-being on VAS (range=0-10, left end of line=very well, right end=very poor), normalized erythrocyte sedimentation rate (ESR) (range=0-10, If ESR is ≤20 mm/h, set to 0. If ≥120 mm/h, set to 10 mm/h. If \> 20 mm/h and \< 120 mm/h, apply formula: \[ESR-20 mm/h\]/10 mm/h), and a count of active arthritis (swelling present or pain present and limitation of motion) in 71 selected joints (range=0-71). JADAS-71 is sum of 4 component scores, range=0-101. A higher score=more arthritis disease activity. Data reported for up to Week 52 was collected in Part 2: Q3W arms: Baseline, Weeks 3,6,9,12,24,36,48 and 51; Q4W arms: Baseline, Weeks 0,4,8,12,24,36 and 40.
| score on a scale | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 0.60 ± 0.839 | 0.21 ± 0.247 | 0.00 ± NA | 0.35 ± 0.295 |
| Week 0 | — | — | 0.00 ± NA | 0.13 ± 0.242 |
| Week 3 | 1.60 ± 2.474 | 0.61 ± 0.913 | — | — |
| Week 4 | — | — | 0.00 ± NA | 0.17 ± 0.266 |
| Week 6 | 0.54 ± 0.812 | 0.39 ± 0.498 | — | — |
| Week 8 | — | — | 0.00 ± NA | 0.20 ± 0.490 |
| Week 9 | 2.59 ± 5.402 | 0.33 ± 0.420 | — | — |
| Week 12 | 0.30 ± 0.600 | 0.84 ± 2.318 | 0.00 ± NA | 0.13 ± 0.327 |
| Week 24 | 0.42 ± 0.576 | 0.05 ± 0.084 | 0.00 ± NA | 0.20 ± 0.346 |
| Week 36 | 0.48 ± 0.950 | 0.08 ± 0.150 | 0.00 ± NA | 0.00 ± 0.000 |
| Week 40 | — | — | — | 0.00 ± 0.000 |
| Week 48 | 0.00 ± 0.000 | 0.17 ± 0.289 | — | — |
| Week 51 | 0.00 ± 0.000 | 0.17 ± 0.208 | — | — |
JIA flare was defined as any 3 of the 6 core outcome variables worsening by at least 30% relative to baseline visit of Part 2, with no more than 1 of the remaining variables improving by more than 30%. For the number of joints with active arthritis or the number of joints with limitation of motion a minimum worsening of at least 2 joints had to be present. If the physician global assessment (PGA) or the parent/patient global assessment were used a minimum worsening of at least 2 units on a scale from 0 to 10 had be present. For erythrocyte sedimentation rate (ESR), a worsening of at least 30% was not considered if within normal ranges. The 6 core outcome variables: PGA of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis, number of joints with limitation of movement, ESR (measure of acute phase reaction) and functional ability determined by Childhood Health Assessment Questionnaire (CHAQ) Disability Index.
| Participants | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study | 1 | 3 | 0 | 1 |
Absence of fever at screening visit was defined as a temperature measurement \< 38 degree centigrades (C). Presence of fever at each study visit was defined as a temperature measurement ≥ 38 C.
| Participants | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study | 0 | 0 | 0 | 0 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Participants | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W |
|---|---|---|---|
| Number of Participants With at Least One Adverse Event | 16 | 7 | 14 |
| pg/mL | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 36.340 ± 19.2413 | 23.453 ± 12.1440 | 51.500 ± NA | 25.415 ± 15.0174 |
| Week 0 | — | — | — | 33.000 ± 23.3195 |
| Week 3 | 61.617 ± 75.5724 | 22.727 ± 7.0321 | — | — |
| Week 4 | — | — | 13.700 ± NA | 28.364 ± 24.8937 |
| Week 6 | 46.698 ± 50.7148 | 82.995 ± 216.2854 | — | — |
| Week 8 | — | — | 14.300 ± NA | 30.580 ± 22.0335 |
| Week 9 | 45.231 ± 46.2539 | 47.582 ± 37.2259 | — | — |
| Week 12 | 84.100 ± 57.8972 | 71.867 ± 156.4710 | 11.600 ± NA | 29.662 ± 26.0053 |
| Week 24 | 79.200 ± 44.8853 | 23.420 ± 14.5520 | 45.000 ± NA | 29.393 ± 19.2760 |
| Week 36 | 67.467 ± 84.7317 | 30.025 ± 16.5470 | 14.100 ± NA | 21.500 ± 15.8392 |
| Week 40 | — | — | — | 22.820 ± 24.0133 |
| Week 48 | 14.533 ± 1.4154 | 15.400 ± 10.0936 | — | — |
| Week 51 | 17.523 ± 9.2077 | 5.060 ± NA | — | — |
| ngEq/mL | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 621.04 ± 443.779 | 735.16 ± 310.983 | 447.00 ± NA | 855.00 ± 325.572 |
| Week 0 | — | — | 72.50 ± NA | 722.83 ± 229.530 |
| Week 3 | 632.43 ± 261.172 | 707.73 ± 291.228 | — | — |
| Week 4 | — | — | 379.00 ± NA | 653.00 ± 143.386 |
| Week 6 | 518.67 ± 272.217 | 721.73 ± 253.114 | — | — |
| Week 8 | — | — | 434.00 ± NA | 628.50 ± 145.891 |
| Week 9 | 596.58 ± 318.685 | 646.92 ± 174.932 | — | — |
| Week 12 | 656.80 ± 123.611 | 666.75 ± 144.510 | 411.00 ± NA | 645.33 ± 106.952 |
| Week 24 | 574.54 ± 347.127 | 554.33 ± 124.498 | 519.00 ± NA | 546.25 ± 330.265 |
| Week 36 | 492.50 ± 258.445 | 646.00 ± 198.499 | 439.00 ± NA | 599.75 ± 122.200 |
| Week 40 | — | — | — | 609.50 ± 115.613 |
| Week 48 | 551.00 ± 91.000 | 391.00 ± 220.293 | — | — |
| Week 51 | 651.00 ± 135.765 | 517.00 ± 140.007 | — | — |
| mg/L | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 4.844 ± 12.2832 | 2.309 ± 6.9847 | 0.200 ± NA | 0.958 ± 1.8575 |
| Week 0 | — | — | 0.610 ± NA | 0.200 ± 0.0000 |
| Week 3 | 0.223 ± 0.0427 | 0.216 ± 0.0407 | 0.200 ± NA | 0.200 ± 0.0000 |
| Week 4 | — | — | 0.200 ± NA | 0.200 ± 0.0000 |
| Week 6 | 0.291 ± 0.1499 | 0.526 ± 1.0163 | — | — |
| Week 8 | — | — | 0.200 ± NA | 0.200 ± 0.0000 |
| Week 9 | 0.208 ± 0.0179 | 0.255 ± 0.1250 | 0.200 ± NA | 0.200 ± 0.0000 |
| Week 12 | 0.200 ± 0.0000 | 0.238 ± 0.1201 | 0.200 ± NA | 0.203 ± 0.0082 |
| Week 24 | 0.280 ± 0.1789 | 0.254 ± 0.1207 | 0.200 ± NA | 4.040 ± 8.5865 |
| Week 36 | 0.225 ± 0.0500 | 0.200 ± 0.0000 | 0.200 ± NA | 0.200 ± 0.0000 |
| Week 40 | — | — | — | 0.200 ± 0.0000 |
| Week 48 | 0.200 ± 0.0000 | 0.820 ± 1.0739 | — | — |
| Week 51 | 0.318 ± 0.2350 | 0.200 ± 0.0000 | — | — |
| mm/h | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 3.43 ± 5.192 | 3.00 ± 1.852 | 1.00 ± NA | 3.17 ± 1.602 |
| Week 0 | — | — | 4.00 ± NA | 2.67 ± 1.633 |
| Week 3 | 2.86 ± 2.035 | 3.57 ± 2.709 | 2.00 ± NA | 2.75 ± 0.957 |
| Week 4 | — | — | 1.00 ± NA | 3.17 ± 1.722 |
| Week 6 | 4.14 ± 4.598 | 4.13 ± 3.681 | — | — |
| Week 8 | — | — | 1.00 ± NA | 3.33 ± 2.160 |
| Week 9 | 2.50 ± 2.510 | 3.23 ± 2.204 | 3.00 ± NA | 2.25 ± 0.957 |
| Week 12 | 2.20 ± 1.789 | 3.92 ± 3.315 | 1.00 ± NA | 4.50 ± 3.209 |
| Week 24 | 2.80 ± 1.304 | 3.17 ± 2.137 | 1.00 ± NA | 2.80 ± 1.789 |
| Week 36 | 2.25 ± 2.217 | 4.50 ± 2.646 | 1.00 ± NA | 2.25 ± 1.893 |
| Week 40 | — | — | — | 2.25 ± 1.893 |
| Week 48 | 3.00 ± 0.816 | 4.67 ± 1.528 | — | — |
| Week 51 | 1.75 ± 1.708 | 6.00 ± 3.000 | — | — |
| Participants | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study | 0 | 0 | 0 | 0 |
| ug/mL | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline | 29.916 ± 35.8002 | 44.210 ± 33.2547 | 9.520 ± NA | 53.622 ± 48.5163 |
| Week 0 | — | — | — | 24.212 ± 13.1659 |
| Week 3 | 26.420 ± 21.1844 | 37.239 ± 21.8192 | — | — |
| Week 4 | — | — | 11.100 ± NA | 17.718 ± 11.1580 |
| Week 6 | 28.636 ± 13.5744 | 30.482 ± 19.2402 | — | — |
| Week 8 | — | — | 22.800 ± NA | 17.578 ± 13.0611 |
| Week 9 | 32.020 ± 6.3739 | 26.962 ± 17.9122 | — | — |
| Week 12 | 37.600 ± 20.5254 | 44.763 ± 77.1798 | 23.800 ± NA | 15.442 ± 11.0714 |
| Week 24 | 24.363 ± 20.3686 | 20.842 ± 25.9417 | 30.300 ± NA | 16.030 ± 14.2124 |
| Week 36 | 30.517 ± 18.6058 | 19.733 ± 8.2218 | 19.800 ± NA | 12.903 ± 11.1808 |
| Week 40 | — | — | — | 28.778 ± 16.0031 |
| Week 48 | 25.433 ± 34.3053 | 22.950 ± 0.9192 | — | — |
| Week 51 | 12.207 ± 8.5862 | 10.945 ± 14.6449 | — | — |
CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability.
| score on a scale | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study | 0.0000 ± 0.00000 | 0.0417 ± 0.09047 | 0.0000 ± NA | 0.0000 ± 0.00000 |
CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability. Negative change from baseline indicates an improvement.
| score on a scale | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Change from Baseline at Week 0 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 3 | 0.2500 ± 0.66144 | 0.0167 ± 0.25384 | — | — |
| Change from Baseline at Week 4 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 6 | 0.1071 ± 0.28347 | -0.0083 ± 0.07420 | — | — |
| Change from Baseline at Week 8 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 9 | 0.2500 ± 0.51539 | -0.0268 ± 0.10022 | — | — |
| Change from Baseline at Week 12 | 0.1250 ± 0.27951 | -0.0481 ± 0.09599 | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 15 | 0.1458 ± 0.35722 | 0.1771 ± 0.54994 | — | — |
| Change from Baseline at Week 16 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 18 | 0.1000 ± 0.22361 | 0.2500 ± 0.85009 | — | — |
| Change from Baseline at Week 20 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 21 | 0.0000 ± 0.00000 | 0.2656 ± 0.90740 | — | — |
| Change from Baseline at Week 24 | 0.1250 ± 0.27951 | -0.0750 ± 0.11180 | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 27 | 0.0000 ± 0.00000 | 0.0000 ± 0.10206 | — | — |
| Change from Baseline at Week 28 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 30 | 0.0000 ± 0.00000 | 0.0000 ± 0.00000 | — | — |
| Change from Baseline at Week 32 | — | — | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 33 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
| Change from Baseline at Week 36 | 0.0000 ± 0.00000 | 0.0417 ± 0.07217 | 0.0000 ± NA | 0.0000 ± 0.00000 |
| Change from Baseline at Week 39 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
| Change from Baseline at Week 40 | — | — | — | 0.0000 ± 0.00000 |
| Change from Baseline at Week 42 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
| Change from Baseline at Week 45 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
| Change from Baseline at Week 48 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
| Change from Baseline at Week 51 | 0.0000 ± 0.00000 | -0.0417 ± 0.07217 | — | — |
Participant's/parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity).
| score on a scale | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study | 2.3 ± 3.95 | 1.6 ± 2.29 | 0.0 ± NA | 2.5 ± 3.21 |
Participant's/Parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity). Reported is the change from baseline in VAS score with a negative change from baseline indicating an improvement.
| score on a scale | Part 2: TCZ IV 12 mg/kg Q3W | Part 2: TCZ IV 8 mg/kg Q3W | Part 2: TCZ IV 12 mg/kg Q4W | Part 2: TCZ IV 8 mg/kg Q4W |
|---|---|---|---|---|
| Change from Baseline at Week 0 | — | — | 0.0000 ± NA | -1.2 ± 1.60 |
| Change from Baseline at Week 3 | -0.3 ± 2.36 | 2.0 ± 6.12 | — | — |
| Change from Baseline at Week 4 | — | — | 0.0000 ± NA | -1.2 ± 1.26 |
| Change from Baseline at Week 6 | -1.6 ± 3.51 | 2.2 ± 4.55 | — | — |
| Change from Baseline at Week 8 | — | — | 0.0 ± NA | -0.5 ± 3.56 |
| Change from Baseline at Week 9 | 8.4 ± 26.48 | 0.1 ± 2.62 | — | — |
| Change from Baseline at Week 12 | -1.6 ± 3.58 | -0.7 ± 2.32 | 0.0 ± NA | -1.2 ± 2.56 |
| Change from Baseline at Week 15 | -1.5 ± 3.67 | 7.1 ± 29.34 | — | — |
| Change from Baseline at Week 16 | — | — | 0.0 ± NA | -1.5 ± 1.97 |
| Change from Baseline at Week 18 | -1.4 ± 3.71 | 6.9 ± 23.26 | — | — |
| Change from Baseline at Week 20 | — | — | 0.0 ± NA | -1.6 ± 2.61 |
| Change from Baseline at Week 21 | 0.0 ± 0.00 | 9.9 ± 30.02 | — | — |
| Change from Baseline at Week 24 | -1.8 ± 4.02 | -0.8 ± 2.17 | 0.0 ± NA | -1.0 ± 2.00 |
| Change from Baseline at Week 27 | 0.0 ± 0.00 | 0.3 ± 2.87 | — | — |
| Change from Baseline at Week 28 | — | — | 0.0 ± NA | -1.2 ± 2.39 |
| Change from Baseline at Week 30 | 0.0 ± 0.00 | -0.3 ± 2.52 | — | — |
| Change from Baseline at Week 32 | — | — | 0.0 ± NA | 5.4 ± 14.35 |
| Change from Baseline at Week 33 | 25.0 ± 50.00 | 0.0 ± 3.00 | — | — |
| Change from Baseline at Week 36 | 0.3 ± 0.50 | 0.0 ± 3.00 | 0.0 ± NA | -2.0 ± 2.83 |
| Change from Baseline at Week 39 | 0.3 ± 0.50 | -1.0 ± 1.73 | — | — |
| Change from Baseline at Week 40 | — | — | — | -2.7 ± 3.06 |
| Change from Baseline at Week 42 | 0.0 ± 0.00 | -0.7 ± 2.08 | — | — |
| Change from Baseline at Week 45 | 0.0 ± 0.00 | 0.3 ± 3.51 | — | — |
| Change from Baseline at Week 48 | 0.0 ± 0.00 | 0.7 ± 4.04 | — | — |
| Change from Baseline at Week 51 | 0.0 ± 0.00 | 0.3 ± 3.51 | — | — |
Collected over Part 1 - Up to 24 weeks plus 12 weeks safety follow up; Part 2 - Up to 52 weeks plus 12 weeks safety follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Tocilizumab (TCZ) Q2W | 0/19 (0%) | 1/19 (5.3%) | 16/19 (84.2%) |
| Part 2: TCZ IV 12 mg/kg Q3W/Q4W | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Part 2: TCZ IV 8 mg/kg Q3W/Q4W | 0/15 (0%) | 1/15 (6.7%) | 14/15 (93.3%) |
| Event | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 0/19 | 1/7 | 0/15 |
| HYPERTRANSAMINASAEMIAHepatobiliary disorders | 0/19 | 0/7 | 1/15 |
| HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSISImmune system disorders | 1/19 | 0/7 | 0/15 |
| Event | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W |
|---|---|---|---|
| PHARYNGITISInfections and infestations | 0/19 | 2/7 | 0/15 |
| URINARY TRACT INFECTIONInfections and infestations | 2/19 | 2/7 | 2/15 |
| ARTHROPOD BITEInjury, poisoning and procedural complications | 3/19 | 2/7 | 0/15 |
| RASHSkin and subcutaneous tissue disorders | 3/19 | 2/7 | 0/15 |
| LEUKOPENIABlood and lymphatic system disorders | 0/19 | 0/7 | 3/15 |
| NEUTROPENIABlood and lymphatic system disorders | 1/19 | 1/7 | 3/15 |
| NASOPHARYNGITISInfections and infestations | 1/19 | 1/7 | 3/15 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/19 | 0/7 | 3/15 |
| EAR PAINEar and labyrinth disorders | 0/19 | 1/7 | 0/15 |
| EAR SWELLINGEar and labyrinth disorders | 0/19 | 1/7 | 0/15 |
Part 1 enrolled 19. Patients treated with TCZ Q2W either during Part 1 or prior to the study, who experienced laboratory abnormalities and which had resolved, were allowed to enroll into Part 2. Part 2 enrolled 22 with 6 from Part 1 and 16 directly enrolled into Part 2. Baseline Characteristics are presented separately for Part 1 and Part 2.
| Age, Continuous(years) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 3.6 | — | — | 8.5 ± 3.6 |
| Age, Continuous(years) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Mean | — | 6.7 ± 1.8 | 11.7 ± 2.8 | 10.1 ± 3.4 |
| Sex: Female, Male(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Female | 9 | 0 | 0 | 9 |
| Male | 10 | 0 | 0 | 10 |
| Sex: Female, Male(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Female | 0 | 4 | 10 | 14 |
| Male | 0 | 3 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 0 | 0 | 6 |
| Not Hispanic or Latino | 13 | 0 | 0 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 4 | 6 |
| Not Hispanic or Latino | 0 | 5 | 10 | 15 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 17 | 0 | 0 | 17 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: Tocilizumab (TCZ) Q2W | Part 2: TCZ IV 12 mg/kg Q3W/Q4W | Part 2: TCZ IV 8 mg/kg Q3W/Q4W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 2 | 3 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 6 | 12 | 18 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2013 to primary completion in Oct 2019, 75 months.
Results were first posted in Apr 2020, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab